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Abstract
Background—Activatable near-infrared fluorescent (NIRF) probes have been used for ex vivo 
and in vivo detection of intestinal tumors in animal models. We hypothesized that NIRF probes 
activatable by cathepsins or MMPs will detect and quantify dextran sulphate sodium (DSS) 
induced acute colonic inflammation in wild type (WT) mice or chronic colitis in IL-10 null mice 
ex vivo or in vivo.
Methods—WT mice given DSS, water controls and IL-10 null mice with chronic colitis were 
administered probes by retro-orbital injection. FMT2500 LX system imaged fresh and fixed 
intestine ex vivo and mice in vivo. Inflammation detected by probes was verified by histology and 
colitis scoring. NIRF signal intensity was quantified using 2D region of interest (ROI) ex vivo or 
3D ROI-analysis in vivo.
Results—Ex vivo, seven probes tested yielded significant higher NIRF signals in colon of DSS 
treated mice versus controls. A subset of probes was tested in IL-10 null mice and yielded strong 
ex vivo signals. Ex vivo fluorescence signal with 680 series probes was preserved after formalin 
fixation. In DSS and IL-10 null models, ex vivo NIRF signal strongly and significantly correlated 
with colitis scores. In vivo, ProSense680, CatK680FAST and MMPsense680 yielded significantly 
higher NIRF signals in DSS treated mice than controls but background was high in controls.
Conclusion—Both cathepsin or MMP-activated NIRF-probes can detect and quantify colonic 
inflammation ex vivo. ProSense680 yielded the strongest signals in DSS colitis ex vivo and in vivo, 
but background remains a problem for in vivo quantification of colitis.
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Inflammatory disorders of the small bowel and colon span a clinical spectrum from acute 
mucosal injury and transient inflammation to chronic inflammatory bowel diseases (IBD), 
such as ulcerative colitis (UC) and Crohn’s disease (1). Clinical presentation combined with 
conventional endoscopy/ileocolonoscopy and histopathology represent the mainstays of 
diagnosis and detection of intestinal inflammatory diseases (1, 2). Additional imaging 
methods are desirable to improve detection and diagnosis of inflammation in the small or 
large intestines (3–5).
There is expanding interest in the application of optical imaging with near infrared 
fluorescent (NIRF) probes to detect inflammation. Imaging in the near infrared (NIR) region 
has potential advantages for deep tissue imaging, and can minimize light scattering and 
problems associated with non-specific tissue autofluorescence at low wavelengths (6–8). 
NIRF probes activated by cathepsins and matrix metalloproteinases (MMPs) have been used 
for in vivo imaging of inflammation in several organs in rodent models although emphasis to 
date has been on superficial organs rather than more deeply situated organs such as colon 
(6).
Cathepsins and MMPs are known to be up-regulated in human IBD and preclinical models 
such as acute intestinal injury and inflammation induced by dextran sulfate sodium (DSS) or 
chronic colitis in the interleukin-10 (IL-10) null mouse (9–14). A majority of studies in IBD 
or animal models have evaluated cathepsins and MMPs at the level of expression of mRNA 
or protein (9, 15–18) and multiple isoforms of these enzymes are expressed in normal or 
inflamed intestine (9, 16, 18). The ability to detect and quantify activated cathepsins or 
MMPs ex vivo or in vivo may provide advantages for detection and localization of intestinal 
inflammation and evaluation of disease severity in high throughput preclinical studies. In the 
present study, a series of commercially available near infrared fluorescence (NIRF) probes 
activated by cathepsins or MMPs were compared for ex vivo or in vivo detection of 
inflammation in the colon of mice with DSS induced acute colonic injury and inflammation. 
A subset of probes was also tested in the IL-10 null model of chronic colitis. The probes are 
summarized in Table 1 and comprise polymer-based substrates that are internally quenched 
by the near infrared fluorophores loaded onto the backbone structure, but are activated to 
emit NIRF when cleaved by cathepsins or MMPs (19). ProSense and MMPSense probes 
have been successfully used to detect inflammation in preclinical models of asthma (20) and 
atherosclerosis (21) and have been widely used to detect tumors, including intestinal tumors 
(22, 23). However, their utility for detection and quantification of colonic inflammation has 
not been quantitatively evaluated or compared. A probe with high specificity for cathepsin K 
was also tested in this study because immunohistochemical studies suggest that cathepsin K 
may have diagnostic potential in Crohn’s disease (17). Our specific goals in this study were 
to define if one or more probes reliably detects and quantifies experimental inflammation ex 
vivo or in vivo and to compare cathepsins and MMP-based probes activated at 680 or 750 
wavelengths as well as new FAST probes which permit more rapid imaging.
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Several fluorescence-based imaging techniques are available. Macroscopic fluorescence 
reflectance imaging (FRI) is a useful technique when probing superficial structures (<5mm 
deep). In this study, FRI was tested for ability to detect and quantify inflammation ex vivo in 
the colon of DSS and IL-10 null models. Ability to detect inflammation based on activated 
probe was evaluated in both freshly dissected and fixed tissues. The ability to detect and 
quantify inflammation in fixed tissue offers potential advantages for studies in large 
numbers of animals. Fluorescence molecular tomography (FMT) potentially permits three-
dimensional (3D) and deep localization and quantification of fluorescent probes in vivo. 
FMT was used for in vivo live imaging in the DSS model to assess whether FMT could 
reliably detect colonic inflammation.
Signals obtained with the most promising probes were tested for correlations with histologic 
scoring of disease severity. Our study demonstrates that both cathepsin and MMP-activated 
probes detect and quantify colonic inflammation ex vivo with 680 activated probes providing 
stronger signals than 750 or FAST probes. Probes show promise for in vivo monitoring but 
improved background and ROI imaging specifically targeted to the colon is desirable.
Materials and Methods
Mouse models
All animal studies were approved by the Institutional Animal Care and Use Committee 
(IACUC) of the University of North Carolina at Chapel Hill (Protocol number: 13-162).
WT C57BL6 mice were used for DSS induced acute mucosal injury and inflammation 
studies. Adult (8–12 weeks) mice were given 3% DSS (TdB consultancy AB, Sweden) in 
drinking water for 5 days, then switched to water for the following 4 days. Mice were 
studied four days after cessation of DSS since prior studies demonstrated that acute DSS-
induced inflammation is maximal at 3–4 days after DSS (24). Mice given free access to 
water served as H2O controls. Control imaging experiments revealed autofluroescence of 
chow diet and fecal pellets from chow fed mice at NIR wavelengths which could be 
minimized by feeding a liquid diet (see supplemental figure 1 and details of control imaging 
experiments below). Therefore, both DSS-treated mice and water controls were given liquid 
diet (Nestle Nutrition, Minnetonka, MN) (Nutren 1.0 Fiber : dH2O=1:1) instead of normal, 
solid chow for 4 days before in vivo imaging to clear the bowel of solid fecal matter and 
minimize autofluorescence. Liquid diet was prepared fresh daily and given ad libitum in 
mouse feeding bottles (Cat. 9019 and 9015, Bio-serv, Frenchtown, NJ). The mice were 
housed in cages with wire mesh bottoms to prevent coprophagia. Water was provided ad lib 
throughout the period of liquid diet feeding.
Germ-free IL-10 null and WT mice on 129 SvEv background were obtained from the 
Gnotobiotic rodent models core facility at UNC-CH and were transferred to a specific 
pathogen free (SPF) facility for 4 months before imaging experiments to allow spontaneous 
chronic colitis to develop in the genetically susceptible IL-10 null mice. As with DSS, IL-10 
null and WT mice were given liquid diet prior to imaging.
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The commercially available enzyme activatable NIRF imaging probes (PerkinElmer) listed 
in Table 1. were given via retro orbital injection. All probes are optically silent until cleaved 
and activated by proteases. The fluorophore on 680 series probes is excited by light at 
680±10 nm and emits light at 700±10nm. The fluorophore on 750 series probes is excited at 
750nm and emits at 770nm. ProSense 680, ProSense 750 and MMPSense 680 were given to 
animals 24 hours before imaging according to manufacture instructions (PerkinElmer). 
FAST (Fluorescent Activatable Sensor Technology) imaging agents designed to permit 
earlier imaging were given 6 hours before imaging as per manufacture instructions 
(PerkinElmer). Each probe was diluted in 1X phosphate buffered saline (1X PBS) before 
injection and at doses recommended by the manufacturer. Published reports indicate up-
regulation of both cathepsins and MMPs in damaged and acutely inflamed colon of DSS 
treated mice (12, 13). The peptide substrate of ProSense 680 is activated by proteases such 
as cathepsin B, L, S and plasmin with reportedly highest specificity for cathepsin B (21). 
MMPSense substrate is cleaved by key MMPs including MMP-2, -3, -9 and -13 with 
reportedly highest specificity for MMP-9 (according to manufacturer).
Control ex vivo imaging experiments—Prior to large scale experiments, with multiple 
activatable NIRF probes in DSS or IL-10 null mice, control experiments were performed to 
ensure minimal background autofluorescence. Imaging of fecal pellets from chow fed WT 
mice reveal autofluroscence (Supplemental Figure 1A). Imaging of chow diet alone also 
revealed autofluroescence whereas a liquid diet had minimal autofluorescence 
(Supplemental Figure 1B). Imaging of fecal pellets from water controls or DSS treated mice 
given no probe injection revealed higher autofluorescence of fecal pellets from water 
controls versus DSS treated mice (Supplemental Figure 1C). This autofluorescence and 
difference between water controls was eliminated by liquid diet feeding for 4 days before 
imaging (Supplemental Figure 1D). Together, these pilot studies led us to use liquid diet 
feeding prior to probe injection and imaging as a standard protocol. Ex vivo imaging of 
small intestine and colon from water controls or DSS treated mice given the liquid diet 
protocol but no probe injection, then subject to FRI imaging at the 680 or 750 wavelength 
demonstrated minimal background and no difference between water controls and DSS 
treated mice (Supplemental Figures 1E and 1F). Together the findings from these 
experiments suggested that pre-imaging liquid diet and inclusion of no probe controls, and 
disease-free controls given probe represent important controls to minimize background 
autofluorescence and validate specificity of signals in diseased animals. Even with liquid 
diet, we note that is essential to carefully flush luminal contents from colon because remnant 
luminal contents in folds of the proximal colon can represent a source of non-specific 
fluorescence.
Ex vivo tissue FRI imaging in colitis models and controls—Animals were 
euthanized by intraperitoneal (i.p.) injection of Nembutal (100mg/kg body weight/per 
animal) 24 hours or 6 hours (FAST probes) after probe injection. Ileum and colon were 
dissected and gently flushed with ice cold 1X PBS and imaged ex vivo by FRI (fluorescence 
reflectance imaging) (FMT 2500™ LX System, PerkinElmer). Light source energy level, 
exposure time and the distance from specimen to camera are kept the same across animal in 
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each experiment. To quantify fluorescence signals, region of interests (ROIs) were set 
manually to cover entire distal colon and the entire distal half of the proximal colon because 
these are regions typically involved in DSS-induced disease. The size of ROIs across 
animals is similar and examples of ROIs are shown in Figure 1A. The goal was to calculate 
the total counts due to activated probe in the entire ROI (distal colon and distal half of 
proximal colon) for each animal. The unit (counts/energy) in ex vivo FRI represents the 
counts per pixel, normalized to laser energy level. The total counts reflect the total amount 
of fluorescence in the entire ROI for each animal, treatment group or probe. During FRI 
imaging with each probe, the imaging system automatically adjusts the scale to encompass 
the minimum-maximum of the signal for optimal visualization with that particular probe. A 
higher scale reflects a stronger signal. Diseased and control animals (DSS and water controls 
or IL-10 null and WT) were always imaged in the same experiment. With each probe, mean 
of total count per ROI in controls was subtracted from the total counts per ROI for each 
diseased animal or water control as a measure of specific probe activation.
We note that the calculation of total counts per ROI was used in this study instead of ‘target 
to background ratio’ which is commonly used in other applications as a measure of 
difference in signal intensity between tumor versus normal tissue (20, 21, 25). This is 
because a major goal was to test if the NIRF signal in the entire colon ROI can estimate 
disease severity. A second goal was to test which of the different probes tested yielded 
significantly higher NIRF signal in colitis models than the background observed in non-
diseased controls.
Intestinal tissue fixation and re-imaging
Immediately after ex vivo imaging of freshly dissected small intestine or colon, tissues were 
fixed in 10% zinc formalin for 24 hours, then kept in 1 X PBS at 4°C before re-imaging to 
test if fluorescent signal was preserved. Tissue was kept in the dark during both fixation and 
storage. Our pilot studies (Supplemental Figure 2) indicated that 10% zinc formalin fixation 
preserved activated ProSense 680 probe better than 4% paraformaldehyde (PFA) fixation. 
The impact of formalin fixation was therefore evaluated on the signal obtained with each of 
the other probes tested.
Co-localization of ProSense680 activation with Cathepsin B immunofluorescence staining
Cathepsin B was stained by immunofluorescence on formalin fixed, paraffin embedded 
sections of colon from DSS treated mice. Sections were deparaffinized in xylene, rehydrated 
in graded ethanol solutions, pretreated with 0.05M Tris Triton (TT) epitope retrieval 
solution at room temperature (RT) for 30 minutes and blocked in 5% normal goat serum 
(NGS) diluted in TT buffer for 1 hr. Cathepsin B antibody (Abcam, Cat# ab33538) was 
diluted in 5% NGS/TT buffer and sections were incubated with primary antibody overnight 
at 4°C in a humidity chamber. After washing 3 times in 0.05M Tris buffer, the sections were 
incubated with secondary antibodies for 1 hour at room temperature. Following three washes 
with 0.05M Tris, coverslips were mounted in gel-mount with DAPI (Electron Microscopy 
Sciences, Hatfield, PA). Activated ProSense 680 probe and cathepsin B 
immunofluorescence were both imaged in the same sections using a Leica TCF SPE 
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confocal microscope (Leica, Bannockburn, IL) and an excitation wavelength of 680nm and 
emission wavelength of 710nm.
Histological scoring and comparison with quantitative data for NIRF probe activation
The distal half of the colon of DSS-treated mice or IL-10 null mice was divided into 8–9 
segments, paraffin embedded, and hematoxylin and eosin (H&E) stained sections prepared 
from each segment. H&E stained sections were scored for inflammation and injury 
according to previously published methods (24). Histological scoring on each segment was 
performed by three independent investigators blinded to treatment group and averaged for 
inflammation severity, inflammation infiltration and crypt loss. Colon from 129 SvEv IL-10 
null mice was scored as previously described (26). Probe activation in each segment was 
quantified by ex vivo FRI imaging. Linear regression analysis compared histological scores 
and 2D FRI quantification data for each colon segment.
In vivo imaging—For in vivo imaging, mice were anesthetized with Nembutal (50mg/kg 
body weight) via i.p. injection and abdominal and torso hair was removed using Nair lotion 
(Ovation Pharmaceuticals Inc. Deerfield, US) to permit light transmission. Anesthetized 
mice were then carefully positioned into the imaging cassette and placed into the imaging 
chamber of the FMT 2500™ LX system. This system uses an NIR laser diode to 
transilluminate (passedight through) the body of the mouse and a thermoelectrically cooled 
CCD camera placed on the opposite side of the imaged animal detects NIRF signal. Optical 
filters collect both excitation and emission fluorescence datasets. The multiple emitted 
fluorescence datasets were normalized to the default laser excitation data (set by 
manufacturer) to calculate signals. The entire image acquisition sequence took 
approximately 3–5 min per mouse.
3D ROI analysis quantified fluorochrome in the entire abdominal area of each mouse. 
Images were displayed as rotatable reconstructed datasets, allowing views in transverse, 
sagittal and coronal planes. A threshold was applied to all animals equal to 30% of the mean 
signal intensity in ROIs of water control mice. Total amount of fluorochrome in the target 
ROI was then automatically calculated from the reconstructed images using FMT’s 
TrueQuant Imaging Software (Ver. 2.0.0.19) and pre-acquired calibrations for each specific 
probe. Data are expressed as absolute total pmol of activated fluorescent probe per animal 
based on comparison with fluorescence of a phantom containing known amounts of 
activated probe imaged with FMT 2500LX. To calculate the extent of probe activation in 
DSS treated mice versus water controls, the mean signal in water controls was subtracted 
from the signal observed in each individual DSS treated animal.
Statistical Analysis
Total NIRF signal per colon ROI was calculated for each DSS or H2O treated animal 
injected with each probe. The mean value in probe injected water controls run in the same 
experiment was subtracted from each individual value to normalize for background. Data for 
each treatment group and probe were then expressed as mean ± SE. Students test for 
significant difference in the mean signal obtained in DSS versus water controls injected with 
the same probe. ANOVA tested for significant differences in mean signals in DSS treated 
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animals injected with each of the different probes. Tukey’s post hoc test was then used for 
comparisons between probes.
Results
Ex vivo imaging reveals strong and significant activation of all probes in distal colon of 
DSS treated mice
Ex vivo FRI imaging and 2D quantification were performed on dissected ileum, proximal 
colon and distal colon of DSS-treated mice and water controls. Ileum from DSS treated mice 
is a useful negative control as it is well established that DSS induces disease in colon and 
not small intestine, with disease most severe in distal colon (27). Representative 2D FRI 
images from probe injected H2O controls and DSS treated animals are shown in Figure 1. 
Figure 1 demonstrates that all probes yielded intense signals in distal colon of DSS-treated 
mice with little or no detectable signal in ileum of DSS treated mice. Signals were 
undetectable or very low in colon and ileum of water controls (Figure 1). Note that the 
pseudocolor scale for each probe is different. For each probe, the scale is auto-adjusted to 
minimum-maximum of the signal for optimal visualization, but with each individual probe 
the same scale is used for DSS and water controls. A lower maximum value for each probe 
reflects a weaker signal. Total counts in the distal colon and distal half of the proximal colon 
from 4–9 animals in each group (treatment or particular probe) were quantified to assess the 
absolute increase in signal in colon of DSS-treated mice vs. mean signal in water controls. 
Mean and SEM of signals obtained with each of the tested probes are illustrated in Figure 
1H. Each probe tested yielded signals in colon ROI of DSS treated mice that were 
significantly above background in water controls. Of the probes tested in DSS-treated mice, 
ProSense 680 yielded the highest signals compared with signals obtained with other probes 
and ProSense 680, CatK fast and Prosense 750 yielded signals that were significantly higher 
than other probes tested (p<0.05) (Figure 1H).
Activation of ProSense 680 in distal colon of DSS treated animals was further confirmed by 
confocal microscopy using excitation light at 680 nm while signal was virtually undetectable 
in water controls (Figure 2A). Overlap between immunofluorescence staining observed with 
a cathepsin B antibody and activated ProSense 680 on the same section from DSS-treated 
mice (Figure 2B) provided additional evidence that cathepsin B enzyme activation was 
validly detected by the ProSense 680 activatable probe.
NIRF imaging signal correlates with histological scores for colitis severity
Histologic scoring of colitis was performed on H&E stained sections from different 
segments of colon from DSS-treated mice as illustrated in Figure 3A and 3B. Ex vivo FRI 
quantified NIRF signal for each of the segments (total counts). Linear regression revealed a 
very strong and significant correlation between ex vivo FRI signals obtained for ProSense 
680 and histologic colitis scores. Regression analyses on histologic colitis scores and FRI 
data on colon segments from animals injected with MMP680 or Cat B680 FAST also 
revealed strong and highly significant correlations (MMPSense680 R=0.854, p<0.001; and 
CatB 680 FAST R=0.938, p<0.0001)
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To investigate if FRI signals obtained with activated probes across individual animals 
treated with DSS also correlated with individual colitis scores, five animals were given 
MMP680 and regression analysis performed on FRI data on entire distal colon and distal 
half of proximal colon and histological colitis scores on tissue sections. A strong and 
significant correlation across individual DSS-treated mice (R=0.829; p<0.05) provides 
evidence that NIRF imaging validly detects differences in inflammation severity across 
animals.
Multi-channel imaging of activated MMP or ProSense probes in a single animal detect 
similar patterns of probe activation
One potential advantage of fluorescence optical imaging over other imaging modalities is 
the ability to use multiple imaging channels to quantify activation of multiple probes in a 
single animal (6). To test this in models of colon inflammation, the same DSS-treated mice 
were injected with both cathepsin activatable and MMP activatable probes. Ex vivo images 
obtained by FRI at 680 and 750 excitation wavelengths in the same DSS-treated mouse 
injected with either ProSense 680 and MMPSense 750 FAST or MMPSense 680 + ProSense 
750 are shown in Figure 4. Cathepsin and MMP probe activation detected by individual 
NIRF probes in the colon from the same DSS-treated animal, revealed similar location of 
activation (Figure 4).
10% zinc formalin fixation preserved fluorescence signals from 680 fluorophore 
conjugated probes, but not signals from 750 fluorophore conjugated probes
One potentially useful application of the activatable imaging probes is to offer a rapid and 
objective measure of colitis severity, especially in experiments involving large numbers of 
animals. In such applications, preservation of signal after fixation would offer the 
opportunity to archive samples over the course of large experiments and subsequently 
quantify signals by FRI. Initial studies in tissues from mice injected with ProSense 680 
suggested that 10% zinc formalin preserved the fluorescence signal but 4% PFA did not 
(Supplemental Figure 2). We therefore fixed ileum and colon in 10% zinc formalin in the 
dark for 24 hours and then stored in 1X PBS for at least 3 days. Representative FRI images 
on fresh and fixed tissues are shown in Figure 5. In animals injected with 680 fluorophore 
conjugated probes, FRI imaging of fresh and fixed tissue demonstrated that the strong 
signals in inflamed colon from DSS treated animals were preserved after fixation (ProSense 
680, Cat K 680 FAST, MMPSense 680 and Cat B 680 FAST) (Figure 5A–5D). With 680 
series probes, signals were qualitatively stronger in fixed versus fresh tissue although the 
general pattern of activation was preserved (Figure 5A–D). This was not the case with 750 
series probes. As shown in Figure 5E–5G, signal intensity in the colon from animals injected 
with 750 probes was greatly reduced or absent after fixation. The increased signal after 
fixation observed with 680 probes may be caused by a general background increase since 
FRI on colon of water controls injected with ProSense 680 probe also revealed a 
qualitatively stronger signal in fixed tissue compared with fresh tissue although this is still 
clearly much less than in DSS treated mice (Figure 5H, compare with 5A). However, this 
does emphasize that imaging of fixed tissue from models of inflammation requires parallel 
analyses of appropriate uninflamed controls to account for quantitative changes in 
background with fixation.
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Ex vivo FRI imaging in colon tissue of 129 SvEv IL-10 null mice injected with activatable 
NIRF probes detects inflammation in cecum and colon
Mice on 129 SvEv background with targeted deletion of IL-10 gene spontaneously develop 
microbiota-driven chronic enterocolitis with massive infiltration of lymphocytes, activated 
macrophages, neutrophils and T cells (27, 28). To define whether NIRF probes have the 
ability to detect inflammation in a model of chronic inflammation with some features in 
common with IBD, ex vivo FRI imaging was performed on a group of 129 SvEv IL-10 null 
mice and WT 129 SvEv controls injected with Cat K 680 or MMPSense 680 probes. As 
shown in Figures 6A and 6C, both Cat K 680 FAST and MMP Sense 680 detected strong 
signals in proximal and distal colon and cecum (only MMP Sense 680 shown) of IL-10−/− 
129 SvEv mice while signals were undetectable in ileum of IL-10−/− 129 SvEv or WT 129 
SvEv controls (Figure 6A, 6B). Regression analyses on FRI signals obtained with each probe 
and histologic colitis scores revealed strong and significant correlations (Cat K 680 FAST, 
R=0.724; p<0.05; MMP Sense 680 R=0.757; p<0.05). Thus in a model of chronic colitis, 
activatable cathepsin-based NIRF probes detect inflammation in the regions of intestine 
known to be diseased in the IL-10 null model (cecum and colon but not ileum) and NIRF 
signal correlates with histologic disease severity.
Detection of activatable probes in vivo requires strategies to minimize background 
autofluorescence
As well as testing the utility of enzyme activatable probes for ex vivo detection and 
quantification of injury or inflammation, it is highly desirable to identify probes and imaging 
modalities for in vivo monitoring of acute or chronic intestinal inflammation. A major issue 
for successful in vivo imaging is the elimination of potential GI tract auto-fluorescence 
generated mainly by fecal contents. We performed pilot in vivo studies to attempt to 
optimize the GI tract preparation methods before live imaging. Given our findings that 
liquid diet reduced ex vivo autofluorescence, a series of in vivo studies was performed on 
disease-free WT C57BL6 mice to test whether that liquid diet feeding could significantly 
reduce abdominal auto-fluorescence or background for in vivo FMT imaging. Mice were 
either fed with liquid diet for 4 days, or fed with 10% trilyte (PEG-3350, Cat# 
NDC0091-0447-23, Seymour, IN) in water and fasted for 24 hours. The latter prep was 
tested to model bowel preparation used in colonoscopy in humans. Probes (MMPSense 680 
or ProSense 750) were given to a subset of animals fed liquid diet. 3D quantification of total 
fluorescence (pmol) in abdominal ROI was performed in each animal. As shown in Figure 
7A and 7B when imaged at 680nm excitation, the strongest signal was observed in the 
animals that received trilyte and fasting but no probe injection (1199.7±33.4 pmol in ROI). 
Much less signal was detected in mice given 4 days of liquid diet feeding and no probe 
injection (14.9±6.0 pmol), although, we observed a significantly higher signal in the 
abdomen of animals given liquid diet and injected with probes (Figure 7B) indicating 
significant background fluorescence with probes even in animals without disease. Since ex 
vivo imaging had demonstrated minimal fluorescence in small intestine or colon of animals 
given probe after liquid diet in the absence of DSS treatment (Figure 1), we conclude that 
the abdominal signals in animals given MMPSense 680 represent non-specific background. 
Nonetheless these findings demonstrate that fasting overnight combining with 10% trilyte 
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feeding cannot effectively eliminate auto-fluorescence background in GI tract for in vivo 
imaging using NIRF probes, and that 4 days on liquid diet reduced non-specific abdominal 
auto-fluorescence.
The same groups of mice were imaged at 750nm excitation wavelength. Figure 7C shows 
there were no detectable abdominal signals in mice that were not injected with probes, 
regardless of whether the mice were fed with liquid diet or not. Imaging of disease free mice 
after ProSense 750 probe injection revealed strong signals in abdominal area even after 4 
days of liquid diet feeding (Figure 7D). Thus, both MMPSense 680 and ProSense 750 
probes yielded some background fluorescence in the abdominal region of disease free mice 
even when mice were given liquid diet.
To investigate if inflamed bowel can cause more background fluorescence than normal 
bowel in live imaging, we did in vivo imaging on H2O controls and DSS treated mice given 
no probe (Figure 7E, 7F). Imaging at 680nm excitation revealed low fluorescence signals in 
water from both groups of animals and no significant higher fluorescence background was 
observed on DSS controls or DSS treated animals even in the absence of probe but 
background values did not differ between H2O controls (46.4 ± 11.7 pmol in H2O controls 
vs. 48.6 ± 13.6 pmol in DSS mice) (Figure 7E). The same groups of mice were imaged at 
750nm excitation wavelength, and there were no detectable abdominal signals in both 
groups of mice (Figure 7F) indicating that background is lower with 750nm imaging.
In vivo imaging of activatable NIRF probes in water controls versus DSS treated mice
To assess whether activatable probes could detect DSS-induced colonic inflammation in 
vivo, FMT imaging was performed on DSS treated mice and water controls that received 
probe injections. All the animals were given liquid diet feeding for 4 days before imaging. 
Seven probes were tested for in vivo imaging, as tested ex vivo (MMPSense 680, MMPSense 
750 FAST, ProSense 680, ProSense 750, ProSense 750 FAST, Cat B 680 FAST, Cat K 680 
FAST). After FMT imaging, total fluorescence (pmol) was quantified in ROIs over the 
abdomen (see ROIs in Figure 8). Representative images of coronal (Figure 8A) and sagittal 
(Figure 8B) views from mice injected with ProSense 680 or Cat K 680 FAST probes are 
also presented in Figure 8.
Mean FMT data for DSS treated mice injected with each of the seven probes tested is shown 
in Figure 8C. After subtracting the mean fluorescence observed in water controls, only 
ProSense 680, Cat K 680 FAST and MMPSense 680 yielded significantly higher signals in 
DSS treated mice than background observed in water controls. In vivo imaging with probes 
conjugated with 750 florophores and particularly FAST probes (PS750, PS750 FAST, 
MMPSense 750 FAST) did not yield signals significantly higher signals than the 
background observed in water controls. Even though the strongest signals were observed in 
abdomen of DSS treated mice with ProSense 680 probe and Cat K 680 FAST probes, we did 
not observe intense and localized activation signal in the region of the colon of DSS treated 
mice. The non specific signals observed in both diseased animals and water control animals 
could be generated by various sources including fecal contents, activation by skin or due to 
probe being metabolized or concentrated in liver and bladder. Software available with 
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FMT2500 does not currently permit selection of ROI to specifically image the colon in vivo 
and so the background reflects the entire abdominal region.
Discussion
This study tested a series of cathepsin or MMP activatable NIRF probes for utility in ex vivo 
or in vivo detection and quantification of inflammation in two widely used murine models, 
DSS-induced acute injury in WT mice and chronic colitis in mice with targeted disruption of 
both IL-10 alleles. Ex vivo imaging demonstrated that all probes tested yielded strong 
signals in distal colon of DSS treated mice and cecum and colon of IL-10 null mice with 
low-level activation in other non-inflamed regions of intestine or in non-diseased controls. 
Strong and significant correlations between quantitative data for probe activation based on 
FRI ex vivo imaging in colon and colitis scores obtained from histologic sections suggest 
utility of ex vivo imaging with these probes for quantification of inflammation in both acute 
injury/inflammation and chronic colitis models. Some of these probes showed promise for in 
vivo imaging to detect colonic inflammation, but there are still some challenges to be 
overcome, particularly non-specific background and ability to validly localize signal to the 
colon.
The ProSense 680 probe was originally developed based on gene microarray data, which 
demonstrated that cathepsin B is dramatically up-regulated in lung cancer (29). Our prior 
studies and other published studies demonstrated that this probe is useful for ex vivo 
detection of intestinal adenomas in the Apc Min+ model (22, 23) and gastric tumors in a 
SMAD4+/− mice (30). Cathepsin activatable NIRF probes have been used successfully to 
detect inflammation in vivo and ex vivo in preclinical models of asthma (31), arthritis (8) and 
atherosclerosis (21) and one study used a different cathepsin-activatable probe in the 
piroxicam-activated IL-10 null colitis model (35). MMP-activatable probes have been used 
to detect tumors in azoxymethane (AOM) and AOM-DSS models of spontaneous and 
colitis-associated tumors (32). To our knowledge however, MMP probes have not been 
tested previously in acute inflammation or colitis models. Our data demonstrated that both 
cathepsin-based and MMP-based probes successfully detected colonic inflammation in DSS 
and IL-10 null models and therefore could potentially be used in preclinical studies 
monitoring incidence, location or severity of disease.
Use of activatable NIRF probes for detection of colitis ex vivo in mouse models of acute 
injury induced by DSS and chronic colitis due to IL-10 gene disruption
We first tested cathepsin- or MMP-activatable probes in the DSS model of acute colitis, 
which is mediated by DSS-induced injury to the colon epithelium and acute macrophage and 
neutrophil-mediated inflammation. Although not a model of T cell-mediated chronic 
inflammation, the DSS model is widely used to assess mediators of acute inflammation and 
interventions that may impact severity of DSS-induced injury.
Ex vivo, all cathepsin- and MMP-based probes, yielded signals in colon of DSS-treated mice 
that were significantly higher than water controls. Thus both cathepsin- or MMP-activated 
probes appear useful for detecting acute inflammation. FAST probes also showed promise 
but signals were not as strong, possibly because these probes were designed to be quickly 
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biodistributed and metabolized/excreted. It is possible that increasing probe dose could 
enhance signal with FAST probe types. Ex vivo all probes yielded strong signals but the 680 
series probes had the advantage of stronger signal and signal preservation after fixation. This 
could be particularly useful for assays of colitis severity in experiments including large 
number of animals.
Cathepsin B is a cysteine protease produced by macrophages and neutrophils that plays a 
role in promoting colitis in human IBD or DSS induced colitis mouse models (9, 18). 
Significant overlap between NIR fluorescence signal observed with ProSense 680 in 
sections of inflamed colon from DSS treated mice and cathepsin B immunofluorescence 
support the specificity of ProSense 680 in the detection of DSS-induced colitis.
The MMP-based probe MMPSense 680 and cathepsin K based probe Cat K 680 FAST were 
tested in IL-10 null mice, a model of chronic, T cell inflammation with features in common 
with human IBD. Findings that ex vivo imaging detects probe activation in regions known to 
exhibit chronic colitis in the IL-10 null model further support the potential utility of use of 
these probes to monitor and quantify colitis in preclinical IBD models.
The signal intensity of the activated probes correlates with histologic colitis scores
Conventional histology enabled confirmation of colitis disease activity in DSS or IL-10 null 
models versus controls. Data from both DSS induced acute colitis model and IL-10 null 
chronic colitis model suggested that the quantification of activated NIRF probe by FRI 
yielded signals that strongly and significantly correlated with severity of histologic colitis 
score within and across animals tested. These results support the potential utility of NIRF 
probes for use in studies assessing impact of an intervention on colitis severity.
ProSense 680 yields the highest signals in the DSS colitis model ex vivo or in vivo
In a prior study we reported data that ProSense 680 was activated to a much greater degree 
by a tumor in the IL-10 null mouse model than by colitis (23). Our current study suggests 
that ProSense 680 is significantly activated by acute and chronic colon inflammation. For 
clinical GI disease screening and diagnosis, there is a need for more specific probes to 
effectively distinguish inflammation from tumor because proteases are up-regulated in both 
colitis and tumors. Prior studies using microarray-based gene expression profiling on mouse 
colon tumors suggested that MMP-9 is a dramatically up-regulated gene (33). In the present 
study, although MMP-activated probes detected inflammation ex vivo in both DSS and 
IL-10 null models, the strongest signals in ex vivo imaging were observed with ProSense 
680. Similarly, in vivo imaging in DSS treated animals revealed the strongest signals with 
ProSense 680 probe. Thus, both ex vivo and in vivo results indicate that ProSense 680 probe 
is the most effective of commercially available probes for detection of acute DSS-induced 
inflammation of colon. A prior study (34) using a different cathepsin activatable NIRF probe 
reported promising in vivo and ex vivo detection of colitis in the piroxicam-inducible IL-10 
null model. In this study, significantly higher signals than background were obtained with 
FMT-in vivo imaging. Co-registration with MR localized signals to the colon. However, as 
found here, background fluorescence was observed in the colitis model outside of the region 
of the colon, which may reflect secretion of activated cathepsins (34). Background in non-
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diseased controls was somewhat lower in the prior report (34) than in the present study, and 
this may reflect probe-specific differences. Together, the prior and current study suggests 
that in vivo imaging of colitis with NIRF probes will still require some refinements for 
optimal application.
We found that feeding with liquid diet for 4 days reduced but did not eliminate non-specific 
abdominal fluorescence signals and was better than other pretreatments such as Trilyte or 
fasting. Liquid diet even for ex vivo imaging, reduced background fluorescence. This mild 
GI tract preparation was well tolerated by animals treated with DSS or IL-10 null mice with 
colitis. In probe injected control animals, the background signals detected in abdomen ROI 
during in vivo imaging likely derive from probe distribution and activation in liver, bladder, 
skin and joints. Compared with signals detected in water controls, consistently higher in vivo 
fluorescent signals, anatomically localized to the abdominal region, were observed in DSS 
treated animals injected with three different probes (ProSense 680, Cat K 680 FAST and 
MMPSense 680). However, in vivo signals were lowest with probes excited at the 750 nm 
wavelength, and their signal intensity was not higher than that in control animals. The 
probes that yielded the weakest signals during in vivo imaging were also the ones that 
yielded weaker signals ex vivo. More analyses will be needed to establish why particular 
probes are more sensitive for in vivo imaging. It is also note worthy that our in vivo analyses 
probably underestimate the increase in signal in DSS-treated animals as we used a region of 
interest encompassing entire abdomen in both water controls and DSS treated mice to ensure 
we fully detected background signal.
One strategy to improve in vivo imaging is to limit the ROI specifically to the colon. We 
have attempted this and obtained higher signals above background in DSS colitis versus 
water controls. However, specific location of ROI to the colon needs to be better validated 
by comparisons with other methods such as MRI and in multiple mice to account for inter-
animal variability in colon location.
Potential advantages in clinic
There is increasing interest in use of molecular imaging to improve detection and diagnosis 
of IBD (35–37). The current data demonstrating ability to detect and quantify inflammation 
by imaging the surface of colon ex vivo indicates the potential that activatable NIRF probes 
might be combined with colonoscopy to improve disease detection. Recent studies have 
successfully used NIR endoscopy systems in preclinical cancer models to detect esophageal 
adenocarcinoma (38) and colonic adenomas (39, 40). The potential advantages of NIR 
combined with endoscopy include higher sensitivity or lower miss rates. NIR detection on 
medical endoscopes for clinical application has been pioneered for targeting flat and 
depressed colonic neoplasms in clinical imaging (41). Combination of probes with capsule 
endoscopy as we have tested experimentally in preclinical cancer models (23) could also 
offer improved ability to detect small bowel disease. However, there remain significant 
challenges to overcome before activatable NIRF probes might be applied in the clinic with 
conventional colonoscopy or capsule endoscopy. First, the probes must be injected and this 
will require FDA approval and clinical data regarding safety. Secondly, the existing 
cathepsin and MMP probes appear to be activated by both inflammation and precancerous/
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cancerous lesions. Ultimately it would be desirable to identify probes specific to 
inflammation vs. cancer or to different types of inflammation such as acute, infectious or 
chronic. Despite these limitations and challenges, the current findings provide evidence and 
proof of principle that activatable NIRF probes have utility for ex vivo and potentially in 
vivo detection and quantification of colonic inflammation in mouse models and may yield 
significant benefits in terms of time, labor and number of animals needed to monitor disease 
in existing or new rodent models of intestinal inflammation, and for testing of therapies.
Moreover, because one advantage of working in the optical imaging is the ability to image 
multiple fluorochromes, this technique can be expanded to allow the measurement of 
multiple molecular signals. In this study, we demonstrate that both cathepsin- and MMP-
based probes alone or combined successfully detected colitis. Characterizing inflammation 
lesions for activation of multiple molecular mediators even in preclinical studies holds 
promise for better understanding of biologic pathways activated in lesions or response to 
therapies.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Strong and significant activation of all probes were detected in distal colon of DSS 
treated mice by ex vivo FRI imaging
Representative 2D FRI images of fresh intestine from DSS-treated mice versus water 
controls are shown in Figure 1A through Figure 1G. Rectangle ROIs (in purple color) were 
placed on distal colon and distal half of proximal colon to quantify fluorescence signal 
(counts). (H) 2D Quantification of fluorescence signals in colon from DSS-treated animals 
(n=4–9 animal/group). Data are mean±SEM of total counts per colon ROI in each DSS 
treated animal injected with each of the indicated probes after subtraction of the mean value 
in water controls.
I:ileum; PC: Proximal colon; DC: Distal colon
a: p<0.05 vs. PS 680 (ProSense 680)
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Figure 2. ProSense 680 probe activation co-localized with cathepsin B antibody 
immunofluorescence staining
(A) Cathepsin enzyme activation was detected only in colon from DSS treated animal, but 
not in colon from water control animal. (B) Co-localization of ProSense 680 probe 
activation and cathpsin B antibody by immunostaining. White arrows indicate the overlap of 
enzyme activation and cathepsin B antibody staining.
DC: Distal colon
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Figure 3. NIRF imaging signal correlates with histological scores for DSS-induced acute colonic 
inflammation severity
(A) Illustrative photograph of colon segments processed for histologic colitis scoring and 2D 
FRI quantification of NIRF signal obtained with ProSense 680. (B) H&E-stained picture on 
each segment from the same animal. (C) Linear regression analysis on NIRF signal versus 
colitis score from each segment.
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Figure 4. Dual-channel imaging of activated MMPsense or ProSense probes in a single animal 
detects similar patterns of probe activation
(A) Activation of ProSense 680 and MMPSense 750 FAST probes in the same DSS-treated 
animal was detected by ex vivo 2D dual-channel FRI imaging. (B) Activation of MMPSense 
680 and ProSense 750 probes in the same DSS-treated animal was detected by ex vivo 2D 
dual-channel FRI imaging.
I:ileum; PC: Proximal colon; DC: Distal colon
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Figure 5. 10% zinc formalin fixation preserved fluorescence signals from 680 fluorophore 
conjugated probes, but not signals from 750 fluorophore conjugated probes
Fresh ileum and colon from both DSS-treated and water control animals were fixed in 10% 
zinc formalin for overnight and kept in 1XPBS in the dark before re-imaging. Activation 
pattern of 680 fluorophore conjugated probes was preserved after 10% zinc formalin 
fixation (A–D), however, Activation of 750 fluorophore conjugated probes were not retained 
after fixation (E–G). (H) Activation of ProSense 680 is enhanced on fixed versus fresh tissue 
in intestine tissue from water control animal.
I:ileum; PC: Proximal colon; DC: Distal colon
Ding et al. Page 21













Figure 6. Ex vivo FRI imaging in colon tissue of 129 SvEv IL-10 null mice injected with 
activatable NIRF probes detects inflammation in cecum and colon
(A) Strong Cat K 680 FAST probe activation was detected in 129 SvEv IL-10 null mouse 
colon. (B) No fluorescence signal was detected in intestine tissue from 129 SvEv WT mouse. 
(C) Illustrative photograph of colon and cecum segments processed for colitis scoring and 
2D quantification.
I:ileum; PC: Proximal colon; DC: Distal colon
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Figure 7. Liquid diet feeding significantly reduced gastrointestinal auto-fluorescence 
background during in vivo FMT imaging of mice
(A) Representative 3D FMT imaging of mouse abdomen from WT, un-diseased control 
animals that received liquid diet minus or plus MMPSense 680 probe injection or Trylite 
and fasting but not probe. Images were acquired at excitation of 680 nm. Cube ROIs (in 
purple color) were placed on abdomen to quantify the absolute fluorescence signal (pmol). 
(B) Quantification of signal intensity in abdomen demonstrated lower auto-fluorescence 
with liquid diet feeding (no probe or probes versus Trilyte and fasting). Data are presented 
as mean±SEM, n=4–6/group. (C) Representative 3D FMT imaging of mouse abdomen from 
animals that received liquid diet minus or plus ProSense 750 probe injection or Trylite and 
fasting but no probe (n=4–6). Images were acquired at excitation of 750 nm. (D) 
Quantification of signal intensity in abdomen demonstrates that ProSense 750 probe yielded 
background fluorescence signal in probe injected mice but not animals minus probe. (E) 3D 
FMT imaging at 680nm excitation wavelength in H2O control and DSS treated animals 
given no probe injections reveals some background but no difference between H2O and 
Ding et al. Page 23













DSS. (F) 3D FMT imaging at 750 nm excitation wavelength in H2O control and DSS treated 
animals given no probe injections reveals no background.
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Figure 8. In vivo imaging of activatable NIRF probes in DSS treated animals versus water 
controls
(A) Representative 3D FMT images of abdomen on coronal plane from DSS-treated mice 
and water controls injected with ProSense 680 or Cat 680 FAST probes. (B) Representative 
3D FMT images of abdomen on saggital plane from DSS-treated mice and water controls 
injected with ProSense 680 or Cat 680 FAST probes. Cube ROIs (in purple color) were 
placed on the abdomen to quantify the absolute fluorescence signal. (C) 3D Quantification 
of fluorescence signal intensity increase in abdomen from DSS-treated animals (n=4–9 
animal/group). Data were presented as mean±SEM. A threshold was applied to all animals 
in each group equal to 30% of the mean signal intensity in ROIs of water control mice given 
the same probe injections.
a: p<0.05 ProSense 680 and CatK 680 fast vs. other probes; b: p<0.05 vs. MMP750 FAST 
vs. other probes
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Table 1
Activatable NIRF probes used to detect intestinal inflammation
Probes Target Dosage/mouse Injection before imaging
PS 680 Cathepsins 2 nmols/150ul 24 hours
PS 750 Cathepsins 2 nmols/150ul 24 hours
MMPS 680 MMPs 2 nmols/150ul 24 hours
Cat B 680 FAST Cathepsin B 2 nmols/100ul 6 hours
Cat K 680 FAST Cathepsin K 2 nmols/100ul 6 hours
PS 750 FAST Cathepsins 4 nmols/100ul 6 hours
MMPS 750 FAST MMPs 2 nmols/100ul 6 hours
Abbreviation: PS: ProSense; MMPS: MMPSense
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